ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BHC / earnings
TLX (47) IDYA (34) DYN (26) NRIX (46) ⌘ Pro Terminal →

Bausch Health Companies Inc. (BHC) Next Earnings Date & Expected ±12.5% Move

$8.02 -2.19% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.97

Bausch Health Companies Inc. (BHC) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $3.07B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BHC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BHC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Bausch Health Companies Inc. (NYSE: BHC) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $8.02 (-2.19% 1D, market cap $3.07B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, BHC ranks #94 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BHC compare to TLX and IDYA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BHC carries a Roarable C+ (68/100 RQD), trailing P/E of 21.2x, gross margin of —, and ROIC of 7.6%. By comparison, TLX (Telix Pharmaceuticals Limited) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.08B) and IDYA (IDEAYA Biosciences Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -13.8%, cap $3.08B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BHC?
▼

Per BHC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000885590), Bausch Health Companies Inc. generated $10.27B in revenue (+6.7% YoY), $157.0M in net income, and $1.00B in free cash flow against $26.37B in total assets and $20.59B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $7.97 (-0.58%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 9.8% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 68/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.8% avg 90D alpha vs SPY • 56.9% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C+
025507510068
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk C+
Cash (8)Whales (17)SEC (12)Macro (15)CEO (16)
Each axis scored 0–20
12M PRICE TARGET CONE+4.5% Base Target
$10 Bull$8 Base$7 Bear
📬 FREE BHC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BHC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (68/100 Composite)
🔍 WHY BHC SCORES 68/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+16/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 80% Net Buy • Cannibal Buyback (-2.36% YoY Shares)

▼ #1 Drag / Risk Factor: Cash Engine Quality8/20 pts (-12 pt drag)

Capital intensity & 17.7% operating margin leave 12 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
60
Grade C$5.89+9.5% Next Q
Q2 (-2Q)
63
Grade C+$6.45+7.3% Next Q
Q3 (-1Q)
65
Grade C+$6.92+15.9% Next Q
Current
68
Grade C+$8.02+1.8% Hist 90D α
Trajectory: C (60) → C+ (68)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the BHC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 68/100 (C+) score, BHC faces multiple-compression risk if 21.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($6.36) or 200D SMA ($5.72) invalidates the momentum regime and cuts Target Base ($8.38) toward Bear Floor ($6.54).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BHC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BHC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 68%NO 32%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.00 Expected Swing
$7.02 (-12.5%)Spot $8.02$9.02 (+12.5%)
MODEL EARNINGS SETUP GAUGE

BHC Quantitative Pre-Earnings Setup: 68/100

Trailing EPS: $0.42 • YoY Revenue Growth: 6.7%

Model Bullish Setup (68/100)Model Risk Weight (32/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$10.27B$157.0M$1.00B52%
FY 20242024-12-31$9.63B-$46.0M$1.26B52%
FY 20232023-12-31$8.76B-$592.0M$637.9M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating BHC & AI Leaders Without Chasing Tops

  • ✓Institutional whale strikes & implied earnings move audit on BHC
  • ✓How disciplined traders manage risk using pre-published trigger & invalidation levels
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BHC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +45.03%📐 HORIZONTAL RANGE
2026-11-03O $8.91H $8.91L $8.02C $8.02VOL 8.87M
RES: $9.16SUP: $2.90SMA50: $6.36SMA200: $5.72
$9.37$8.00$6.64$5.27$3.91RES $9.16SUP $2.90$8.022026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BHC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BHC Butterfly Map → + Track BHC →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
14.9%/yr Implied 5Y Growth

vs. +6.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BHC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BHC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BHC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BHC)

Health Care Rank #94 of 1015 ⚔️ TLX vs BHC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BHC vs. TLX, IDYA, DYN, NRIX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Bausch Health Companies Inc. (BHC) ranks #94 by composite RQD confidence (68/100, grade C+) and #203 by equity capitalization ($3.07B). Within this direct 5-issuer industry benchmark cohort, BHC leads on earnings valuation at 21.2x trailing P/E, while BHC leads on capital efficiency and profitability with 7.6% ROIC and — gross margin. BHC currently leads its immediate peer cohort in composite quantitative strength at 68/100 (C+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BHC ACTIVE
Bausch Health Companies Inc.
C+ 68/100 21.2x — 7.6% -2.19% $3.07B Benchmark Subject
TLX
Telix Pharmaceuticals Limited
D 47/100 — — — -0.55% $3.08B /tlx-vs-bhc →
IDYA
IDEAYA Biosciences Inc.
E 34/100 — — -13.8% -1.00% $3.08B /idya-vs-bhc →
DYN
Dyne Therapeutics Inc.
E 26/100 — — -35.0% +3.66% $3.12B /dyn-vs-bhc →
NRIX
Nurix Therapeutics Inc.
D 46/100 — — -35.0% -4.10% $2.93B /nrix-vs-bhc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000885590 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bausch Health Companies Inc. (BHC) reported GAAP revenue of $10.27B (+6.7% vs. FY2024 revenue of $9.63B , and +17.2% cumulative change since FY2023) , GAAP net income of $157.0M, operating cash flow of $1.40B, and free cash flow of $1.00B (-20.4% YoY). On the balance sheet, BHC closed FY2025 with $26.37B in total assets against $20.59B in total debt (Altman Z-Score: 0.45, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $10.27B $157.0M $1.40B $1.00B $26.37B $20.59B
FY2024 (FY) 2024-12-31 $9.63B -$46.0M $1.60B $1.26B $26.52B $18.94B
FY2023 (FY) 2023-12-31 $8.76B -$592.0M $1.03B $637.9M $10.51B $2.46B

3. BHC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BHC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Bausch Health Companies Inc. (NYSE: BHC) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $8.02 (-2.19% 1D, market cap $3.07B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, BHC ranks #94 in composite RQD confidence.

How does BHC compare to TLX and IDYA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BHC carries a Roarable C+ (68/100 RQD), trailing P/E of 21.2x, gross margin of —, and ROIC of 7.6%. By comparison, TLX (Telix Pharmaceuticals Limited) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.08B) and IDYA (IDEAYA Biosciences Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -13.8%, cap $3.08B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BHC?

Per BHC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000885590), Bausch Health Companies Inc. generated $10.27B in revenue (+6.7% YoY), $157.0M in net income, and $1.00B in free cash flow against $26.37B in total assets and $20.59B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BHC trading relative to its 50-day, 200-day, and 52-week technical levels?

BHC last traded at $8.02 (-2.19% on volume of 4,943,390 shares), positioning the stock +26.10% above its 50-day simple moving average ($6.36) and +40.21% above its 200-day simple moving average ($5.72). Across its 52-week range of $4.33 to $9.04, BHC sits at the 78.3% percentile with a 14-day RSI of 64.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($7.02 to $9.02).

Direct Sub-Reports: BHC RQD Cockpit BHC 12M Forecast BHC Earnings & Move BHC Dividends & DRIP BHC Insiders & 13F BHC Whale Options BHC Profit Sankey BHC News & Why
ROARABLE RATING BRIEF • RQD 68/100 (C+) ✓ SEC XBRL & RQD VERIFIED

BHC — Bausch Health Companies Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Bausch Health Companies Inc. (BHC) earns a live Roarable RQD composite score of 68/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $8.02 (-2.19% 1D, market capitalization $3.07B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of 7.6%, gross margin of —, operating margin of 17.7%, and free cash flow yield of 22.00%.
  • Whale 13F & Options Flow (17/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (15/20) + Forensic Balance Sheet (12/20): Incorporates a 0.97x equity beta, Altman Z-Score of 0.45, Piotroski F-Score of 9/9, and Debt/Equity of 0.85x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Bausch Health Companies Inc. Is a NYSE-listed company in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry..3B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Bausch Health Companies Inc. (BHC) reported $10.27B in annual revenue (up from $9.63B in FY2024, +6.7% YoY) and $157.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($8.76B revenue, -$592.0M net income) through FY2025, BHC scaled operating cash flow to $1.40B and free cash flow to $1.00B, backed by $26.37B in total assets against $20.59B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C+ • RQD 68/100): Big institutional funds and options desks are actively positioning on the bullish side. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $4.33 – $9.04 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Investors must weigh 21.2x trailing P/E and 10.5x EV/EBITDA against 17.7% operating margins and a 0.97x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context provided is the Health Care sector and Biotechnology: Pharmaceutical Preparations industry classification from the profile, and the beta of 0.97 from the market data, which indicates the stock has tracked broad market movement roughly in line with the market over the measurement period. Investors should note that the absence of mapped links means this brief cannot identify which suppliers, customers, or peers could transmit shocks to BHC.

  • Key Question #1: Can BHC sustain or expand its 17.7% operating margin and 7.6% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $10.27B and free cash flow of $1.00B, how will capital allocation balance growth reinvestment against $20.59B in total debt?
  • Key Question #3: How sensitive is BHC's 19.7x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.97x)?

BHC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Bausch Health Companies Inc. (BHC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BHC Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BHC Bull vs. Bear Conversation Board — What's Your Call at $8.02?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BHC 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BHC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $10.82 (+32.0%)
📌 Pinned Debate

Institutional and options positioning (18/20) plus insider cluster flow (16/20) are the strongest pillars in the rating, alongside a 28

Long BHC at $8.20 targeting $10.82. Institutional and options positioning (18/20) plus insider cluster flow (16/20) are the strongest pillars in the rating, alongside a 28.76% price move.. Institutional whale score is 17/20 and the risk/reward vs. the $4.33 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

@BearTrap_Alert Shorting a 17/20 institutional whale-flow stock at $8.20 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $6.15 (-25.0%)
Spot @ $8.20

The Altman Z-Score of 0.45 and a fundamental cash-engine score of only 8/20 signal weak financial durability behind the stock's recent

I respect the product at Bausch Health Companies Inc., but the stock at $8.20 is a different story. The Altman Z-Score of 0.45 and a fundamental cash-engine score of only 8/20 signal weak financial durability behind the stock's recent rally.. FCF yield is 22.0% and RQD sits at 68/100 (C+) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%